Chong Kun Dang Pharmaceutical Corp.
Symbool: 185750.KS
KSC
101200
KRWMarktprijs vandaag
6.4696
Koers/Winst Verhouding
-0.0542
Koers/Winst Groei Verhouding
1.29T
MRK Kapitalisatie
- 0.01%
DIV Rendement
Chong Kun Dang Pharmaceutical Corp. (185750-KS) Jaarrekeningen
Balans
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 0 | 365065.3 | 155861.2 | 187332.6 | |||||||||||
balance-sheet.row.short-term-investments | 0 | 145418.9 | 38444.3 | 55519.9 | |||||||||||
balance-sheet.row.net-receivables | 0 | 311468.6 | 287306.6 | 234703.7 | |||||||||||
balance-sheet.row.inventory | 0 | 261431.9 | 270081.5 | 224722.9 | |||||||||||
balance-sheet.row.other-current-assets | 0 | 8606.1 | 365.5 | 20387.9 | |||||||||||
balance-sheet.row.total-current-assets | 0 | 946571.9 | 713614.8 | 667147.2 | |||||||||||
balance-sheet.row.property-plant-equipment-net | 0 | 319787.1 | 310697.4 | 298909.7 | |||||||||||
balance-sheet.row.goodwill | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.intangible-assets | 0 | 52527.1 | 26953 | 20805.5 | |||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 0 | 52527.1 | 26953 | 20805.5 | |||||||||||
balance-sheet.row.long-term-investments | 0 | 67179.1 | 5565.5 | -22146.7 | |||||||||||
balance-sheet.row.tax-assets | 0 | 14213.2 | 6208.6 | 2350.3 | |||||||||||
balance-sheet.row.other-non-current-assets | 0 | 2150.1 | 61843.5 | 79634.1 | |||||||||||
balance-sheet.row.total-non-current-assets | 0 | 455856.6 | 411268 | 379552.9 | |||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.total-assets | 0 | 1402428.4 | 1124882.8 | 1046700.1 | |||||||||||
balance-sheet.row.account-payables | 0 | 183938.8 | 145436.3 | 129327.4 | |||||||||||
balance-sheet.row.short-term-debt | 0 | 184767.4 | 124445.5 | 102091.4 | |||||||||||
balance-sheet.row.tax-payables | 0 | 43938.2 | 29026.4 | 18701.1 | |||||||||||
balance-sheet.row.long-term-debt-total | 0 | 30000 | 111292.6 | 134962.3 | |||||||||||
Deferred Revenue Non Current | 0 | 1484.8 | 6438.3 | 5982 | |||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 0 | - | - | - | |||||||||||
balance-sheet.row.other-current-liab | 0 | 134996.6 | 98922.3 | 20691.5 | |||||||||||
balance-sheet.row.total-non-current-liabilities | 0 | 75327.4 | 129380.9 | 160660.6 | |||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.capital-lease-obligations | 0 | 4996.5 | 1694.2 | 3470.5 | |||||||||||
balance-sheet.row.total-liab | 0 | 586793.3 | 503594 | 480890.4 | |||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.common-stock | 0 | 31421.2 | 29970.1 | 28565.2 | |||||||||||
balance-sheet.row.retained-earnings | 0 | 218102.4 | 376370.8 | 302106.6 | |||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 0 | 350829.8 | 276706.4 | 250156.9 | |||||||||||
balance-sheet.row.other-total-stockholders-equity | 0 | 215341.1 | -60654.3 | -14818.7 | |||||||||||
balance-sheet.row.total-stockholders-equity | 0 | 815694.5 | 622393.1 | 566010 | |||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 0 | 1402428.4 | 1124882.8 | 1046700.1 | |||||||||||
balance-sheet.row.minority-interest | 0 | -59.3 | -1104.3 | -200.3 | |||||||||||
balance-sheet.row.total-equity | 0 | 815635.2 | 621288.8 | 565809.6 | |||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 0 | - | - | - | |||||||||||
Total Investments | 0 | 212598 | 44009.8 | 33373.2 | |||||||||||
balance-sheet.row.total-debt | 0 | 219763.9 | 235738.1 | 237053.8 | |||||||||||
balance-sheet.row.net-debt | 0 | 117.5 | 118321.2 | 105241.1 |
Kasstroomoverzicht
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | 0 | 212521.2 | 79977.8 | 42356.5 | |||||||||||
cash-flows.row.depreciation-and-amortization | 0 | 36942.2 | 33597.7 | 27481.9 | |||||||||||
cash-flows.row.deferred-income-tax | 0 | 0 | 0 | 0 | |||||||||||
cash-flows.row.stock-based-compensation | 0 | 0 | 0 | 0 | |||||||||||
cash-flows.row.change-in-working-capital | 0 | 29681.8 | -77299.3 | -71568.7 | |||||||||||
cash-flows.row.account-receivables | 0 | -29559.7 | -51435.9 | -6926 | |||||||||||
cash-flows.row.inventory | 0 | -5980.3 | -54466.2 | -53770.6 | |||||||||||
cash-flows.row.account-payables | 0 | 38583.8 | 15824.5 | -15597.8 | |||||||||||
cash-flows.row.other-working-capital | 0 | 26638 | 12778.2 | 4725.7 | |||||||||||
cash-flows.row.other-non-cash-items | 0 | 39014.7 | 31458.4 | 14634.2 | |||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | 0 | 0 | 0 | 0 | |||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | 0 | -68806 | -53064.7 | -51844.4 | |||||||||||
cash-flows.row.acquisitions-net | 0 | 451.6 | 142.1 | -3448.7 | |||||||||||
cash-flows.row.purchases-of-investments | 0 | -192468.2 | -57181.1 | -61266.4 | |||||||||||
cash-flows.row.sales-maturities-of-investments | 0 | 89470 | 44375.6 | 21934.7 | |||||||||||
cash-flows.row.other-investing-activites | 0 | 39.8 | 347.8 | 3815.5 | |||||||||||
cash-flows.row.net-cash-used-for-investing-activites | 0 | -171312.9 | -65380.3 | -90809.3 | |||||||||||
cash-flows.row.debt-repayment | 0 | -22714.6 | -0.3 | -896.2 | |||||||||||
cash-flows.row.common-stock-issued | 0 | -3335.3 | 0 | 0 | |||||||||||
cash-flows.row.common-stock-repurchased | 0 | -6025 | -1888.4 | -1935.3 | |||||||||||
cash-flows.row.dividends-paid | 0 | -11608.5 | -11238.8 | -10808.3 | |||||||||||
cash-flows.row.other-financing-activites | 0 | -16.5 | -3212.4 | 98778.7 | |||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 0 | -43700 | -16339.8 | 85138.9 | |||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0 | -917.6 | -410.1 | 920.1 | |||||||||||
cash-flows.row.net-change-in-cash | 0 | 102229.4 | -14395.8 | 8153.6 | |||||||||||
cash-flows.row.cash-at-end-of-period | 0 | 219646.3 | 117416.9 | 131812.7 | |||||||||||
cash-flows.row.cash-at-beginning-of-period | 0 | 117416.9 | 131812.7 | 123659.1 | |||||||||||
cash-flows.row.operating-cash-flow | 0 | 318159.9 | 67734.5 | 12903.9 | |||||||||||
cash-flows.row.capital-expenditure | 0 | -68806 | -53064.7 | -51844.4 | |||||||||||
cash-flows.row.free-cash-flow | 0 | 249353.9 | 14669.8 | -38940.5 |
Rij winst-en-verliesrekening
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 0 | 1669404.4 | 1488344.7 | 1343559.4 | |||||||||||
income-statement-row.row.cost-of-revenue | 0 | 1014059.9 | 945705.3 | 847741.1 | |||||||||||
income-statement-row.row.gross-profit | 0 | 655344.5 | 542639.4 | 495818.3 | |||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | |||||||||||
income-statement-row.row.research-development | 0 | - | - | - | |||||||||||
income-statement-row.row.selling-general-administrative | 0 | - | - | - | |||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||||||||||
income-statement-row.row.other-expenses | 0 | -11694.4 | 139957.4 | 135069 | |||||||||||
income-statement-row.row.operating-expenses | 0 | 408657.6 | 432733.3 | 401059.6 | |||||||||||
income-statement-row.row.cost-and-expenses | 0 | 1422717.5 | 1378438.7 | 1248800.7 | |||||||||||
income-statement-row.row.interest-income | 0 | 5789.3 | 2139 | 716.2 | |||||||||||
income-statement-row.row.interest-expense | 0 | 9271 | 6846.9 | 4029.9 | |||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||||||||||
income-statement-row.row.total-other-income-expensenet | 0 | -5283.9 | -12741 | -14164.8 | |||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | |||||||||||
income-statement-row.row.other-operating-expenses | 0 | -11694.4 | 139957.4 | 135069 | |||||||||||
income-statement-row.row.total-operating-expenses | 0 | -5283.9 | -12741 | -14164.8 | |||||||||||
income-statement-row.row.interest-expense | 0 | 9271 | 6846.9 | 4029.9 | |||||||||||
income-statement-row.row.depreciation-and-amortization | 0 | 36942.2 | 34919.3 | 18187.3 | |||||||||||
income-statement-row.row.ebitda-caps | 0 | - | - | - | |||||||||||
income-statement-row.row.operating-income | 0 | 246686.9 | 109906.1 | 94758.7 | |||||||||||
income-statement-row.row.income-before-tax | 0 | 241403 | 97165.1 | 80593.9 | |||||||||||
income-statement-row.row.income-tax-expense | 0 | 27995.7 | 17187.3 | 38237.4 | |||||||||||
income-statement-row.row.net-income | 0 | 212521.2 | 80953.4 | 42720.4 |
Vaak gestelde vragen
Wat is Chong Kun Dang Pharmaceutical Corp. (185750.KS) totale activa?
Chong Kun Dang Pharmaceutical Corp. (185750.KS) totale activa is 1402428435512.000.
Wat is de jaarlijkse omzet van de onderneming?
De jaarlijkse omzet is N/A.
Wat is de winstmarge van de onderneming?
De bedrijfswinstmarge is 0.530.
Wat is vrije kasstroom van de onderneming?
De vrije kasstroom is {free_cash_flow}}.
Wat is de nettowinstmarge van de onderneming?
De nettowinstmarge is 0.122.
Wat is de totale omzet van de onderneming?
De totale opbrengst is 0.146.
Wat is Chong Kun Dang Pharmaceutical Corp. (185750.KS) nettowinst (netto-inkomen)?
De nettowinst is 212521171440.000.
Wat is de totale schuld van het bedrijf?
De totale schuld is 219763880100.000.
Wat zijn de bedrijfskosten?
De bedrijfsuitgaven zijn 408657610015.000.
Wat is het kasstroomcijfer van het bedrijf?
Enretprise cash is 0.000.